A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines
Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: LOU064 (blinded); Drug: Placebo; Drug: LOU064 (open-label)

Sponsors: Novartis Pharmaceuticals

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 6, 2024Comments OffClinicalTrials.gov | Dermatology Clinical Trials | Dermatology Studies | US National Library of Medicine
Comments